3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
24
Salivary Gland Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Biochemically Recurrent Prostate Cancer
1
Advanced Solid Tumor
1
Interventions
Nivolumab
37
pembrolizumab
26
cabozantinib
26
Specimen Handling
23
Magnetic Resonance Spectroscopy
21
Ipilimumab
19
lenvatinib
13
belzutifan
13
Axitinib
13
CTLA-4 Antigen
10
Sunitinib
9
Radiosurgery
8
Biopsy
8
atezolizumab
7
fludarabine
4
avelumab
4
aldesleukin
4
Immunoglobulin G
4
Disulfides
4
zimberelimab
3
toripalimab
3
tivozanib
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
Surveys and Questionnaires
3
Nephrectomy
3
Everolimus
3
Cyclophosphamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
darolutamide
×
90 days
×
Clear all
No trials found.